FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1474-1482 April 3, 2008 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text  Full Text Audio PowerPoint Slide Set Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A 65-year-old asymptomatic man is concerned about his risk of osteoporosis. His mother died after a hip fracture at 74 years of age. The patient has no history of fractures but has lost 7.6 cm (3 in.) in height; he does not smoke and has never taken corticosteroids. He drinks two glasses of beer (16 oz, or about 0.5 liter, each) per . . . [Full Text of this Article]

The Clinical Problem

Secondary Causes of Bone Loss in Men

Natural History of Bone Loss in Men

Strategies and Evidence

Diagnosis

Additional Testing

            Laboratory Tests

            Vertebral-Fracture Assessment

Management

            Nonpharmacologic Therapy

            Pharmacologic Therapy

            Bisphosphonates

            Anabolic Agents

            Testosterone Therapy

Areas of Uncertainty

Guidelines

Conclusions and Recommendations

Source Information

From the Department of Medicine, Royal Melbourne Hospital/Western Hospital, and the Department of Endocrinology, University of Melbourne, Western Hospital, Melbourne, Victoria, Australia.

An audio version of this article is available at www.nejm.org.

Address reprint requests to Dr. Ebeling at the Department of Medicine (RMH/WH), Western Hospital, Gordon St., Footscray 3011, Victoria, Australia, or at peterre@unimelb.edu.au.

Related Letters:

Osteoporosis in Men
Ott S. M., Lems W. F., Geusens P. P.M.M., Joy M., Ebeling P. R.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:868-869, Aug 21, 2008. Correspondence

This article has been cited by other articles:

• Bitton, A., Yialamas, M., Levy, B. D., Katz, J. T., Loscalzo, J. (2009). A Fragile Balance. NEJM 361: 74-79 [Full Text]  
• Barnes, P. J., Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165-1185 [Abstract] [Full Text]  
• Berlin, F. S. (2009). Commentary: Risk/Benefit Ratio of Androgen Deprivation Treatment for Sex Offenders. J Am Acad Psychiatry Law 37: 59-62 [Abstract] [Full Text]  
• Saylor, P. J., Smith, M. R. (2009). Prostate Cancer Survivorship: Metabolic Complications of Androgen Deprivation Therapy. Am Soc Clin Oncol Ed Book 2009: 263-268 [Abstract] [Full Text]  
• Smith, M. R. (2008). Osteoporosis in Men With Prostate Cancer: Now for the Fracture Data. JCO 26: 4371-4372 [Full Text]  
• Ott, S. M., Lems, W. F., Geusens, P. P.M.M., Joy, M., Ebeling, P. R. (2008). Osteoporosis in men.. NEJM 359: 868-868 [Full Text]